Cornell University Patent Portfolio Statistics

tip_user1

Cornell University

Profile Summary

This article summarizes the perfomance of the assignee in the recent years. The overall statistics for this portfolio help to analyze the areas where the assignee is performing well. The filing trend, perfomance across the tech centers and the perfomance of the recent applications has been mentioned below. All the stats are calculated based on the perfomance in USPTO.

How does the overall patent portfolio of Cornell University look like?

Assignee Art Units
Total Applications: 1,964 2,061,582
Granted Patents: 1,248 1,160,152
Grant Index 74.91% ↑ 69.94%
Abandoned/Rejected Applications: 418 (25.09%) 498,618 (30.06%)
In-Process Applications: 296 402,812
Average Grant Time: 3.2 Years ↑ 2.76 Years
Average Office Actions: 2.04 ↑ 1.62

Which Technology Area Cornell University is filing most patents in? (Last 10 years)

Art Unit Definition Total Applications
1634 Molecular Biology, Bioinformatics, Nucleic Acids, Recombinant DNA and RNA, Gene Regulation, Nucleic Acid Amplification, Animals and Plants, Combinatorial/ Computational Chemistry 93
Opap Parked GAU 81
1633 Molecular Biology, Bioinformatics, Nucleic Acids, Recombinant DNA and RNA, Gene Regulation, Nucleic Acid Amplification, Animals and Plants, Combinatorial/ Computational Chemistry 46
1661 Plants 45
1645 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology 43

How many patents are Cornell University filing every year?

Year Total Applications Predicted
2022 0* 774
2021 61* 726
2020 119 612
2019 142 142
2018 123 –
2017 100 –
2016 129 –
2015 134 –
2014 158 –
2013 114 –

*The drop in the number of applications filed in last two years compared to previous years is because applications can take up to 18 months to get published

Recently filed patent applications of Cornell University in USPTO?

Publication number: US20220188601A1
Application number: 17/551,994

Abstract:
A method in an illustrative embodiment comprises obtaining data characterizing a given subject over time, applying at least a portion of the obtained data to an encoder-decoder neural network adapted to generate a prediction of at least one change in at least one of behavior and physiology of the given subject from the obtained data, and executing at least one automated remedial action relating to the given subject based at least in part on the generated prediction. The encoder-decoder neural network is configured to learn one or more subject-specific anomaly thresholds based at least in part on reconstruction error of the encoder-decoder neural network. The encoder-decoder neural network is illustratively implemented utilizing at least one of a fully-connected neural network autoencoder architecture and a gated recurrent unit sequence-to-sequence architecture. Other illustrative embodiments include systems and computer program products.

Publication date: 2022-06-16
Applicant: Cornell University
Inventors: A Adler Daniel

Publication number: US20220088143A1
Application number: 17/546,951

Abstract:
Provided is a method of treating coronary artery disease in a mammal, comprising administering to a region of the heart of the mammal (a) a first vector encoding one or more angiogenic proteins which induce vascularization in the heart of the mammal, and (b) a second vector encoding one or more cardio-differentiating transcription factors which induce the production of induced cardiomyocytes (iCM) in the heart of the mammal, whereby the coronary artery disease in the mammal is treated. In a preferred embodiment, the first vector is an adenoviral vector encoding VEGF and the second vector is a lentiviral vector encoding Gata4, Mef2c, and Tbx5 (GMT).

Publication date: 2022-03-24
Applicant: Cornell University
Inventors: Mathison Megumi

Publication number: US20220226502A1
Application number: 17/615,382

Abstract:
The present disclosure provides enzyme replacement therapy using gene therapy vectors, such as adeno-associated virus (AAV) vectors expressing human Cystathionine Beta-Synthase (CBS) to reduce the amount of serum homocysteine (Hcy) and increase the amount of downstream metabolites, such as cystathionine and cysteine (Cys), which can be used for treatment of diseases, such as homocystinuria and homocysteine remethylation disorders.

Publication date: –
Applicant: Cornell University
Inventors: Kaminsky Stephen

How are Cornell University’s applications performing in USPTO?

Application Number Title Status Art Unit Examiner
17/551,994 System Implementing Encoder-Decoder Neural Network Adapted To Prediction In Behavioral And/Or Physiological Contexts – OPAP Central, Docket
17/546,951 Angiogenic Conditioning To Enhance Cardiac Cellular Reprogramming Of Fibroblasts Of The Infarcted Myocardium Docketed New Case – Ready for Examination OPAP Central, Docket
17/615,382 Adeno-Associated Virus Vector Delivery Of Cystathionine Beta-Synthase (Cbs) Enzyme For Treating Cbs Deficiency Application Undergoing Preexam Processing 1633 –
17/614,022 Devices, Systems, And Methods For Personal Speech Recognition And Replacement Docketed New Case – Ready for Examination OPAP Central, Docket
17/532,285 Dipeptidomimetics As Inhibitors Of Human Immunoproteasomes Docketed New Case – Ready for Examination OPAP Central, Docket